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Abstract  
 
Background: Schizophrenia is a serious, chronic, and often debilitating neuropsychiatric disor-
der. Its causes are still poorly understood. Besides genetic and non-genetic (environmental) fac-
tors are thought to be important as the cause of the structural and functional deficits that 
characterize schizophrenia. This study aimed to compare Toxoplasma gondii infection between 
schizophrenia patients and non-schizophrenia individuals as control group. 
Methods: A case-control study was designed in Tehran, Iran during 2009-2010. Sixty-two pa-
tients with schizophrenia and 62 non-schizophrenia volunteers were selected. To ascertain a 
possible relationship between  T.  gondii  infection and schizophrenia, anti-Toxoplasma  IgG 
antibodies were detected by indirect-ELISA. Data were statistically analyzed by chi- square at a 
confidence level of 99%. 
Results: The sero-positivity rate among patients with schizophrenia (67.7%) was significantly 
higher than control group (37.1) (P <0. 01). 
Conclusion: A significant correlation between Toxoplasma infection and schizophrenia might be 
expected. 
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Introduction 
 
bout 30-60% of the population in 
both developed and developing 
countries are infected with the para-
sitic protozoon  Toxoplasma gondii.  Tox-
oplasma gondii is an intracellular protozoan 
that is widespread globally. Its final hosts 
are felids, but its intermediate hosts are 
almost all the warm-blooded animals (1). 
Humans become infected in 3 ways: 1- 
ingesting T. gondii tissue cysts (containing 
bradyzoites) presented in the undercooked 
meat (especially lamb and pork) of infected 
food animals; 2- ingesting highly infectious 
oocysts (containing sporozoites) presented in 
water, garden soil, children’s sandboxes, etc, 
contaminated by infected cat feces; 3- con-
genital trans-placental transmission of rap-
idly replicating tachyzoites from mothers 
who become infected during pregnancy (2). 
It can exist chronically in tissues and organs 
such as the brain of an immunocompetent 
host in the form of cysts. The host does not 
show any physical symptoms or signs in 
such latent infections (3). 
Bedsides host’s behavior and psychomotor 
skills, T. gondi might change the personality 
as well (1, 3-7). 
Torrey et al. (8) found that cat ownership be-
fore age 13 was a risk factor for the later 
development of psychoses and speculated 
that the transmission of some zoonotic agent 
such as T. gondii between pets and human 
beings may be a possible mechanism for 
schizophrenia. Brown et al. (9) suggested 
that maternal toxoplasmosis increased the 
risk of adult schizophrenia in the offspring. 
Schizophrenic patients infected with  Tox-
oplasma  encompass more levels of anti-
bodies than the same group of non-schizo-
phrenic group (10-12). Moreover, level of 
IgG, IgM, or IgA antibodies to T. gondii, is 
higher in patients with first-episode schizo-
phrenia (13-15). Some medications that had 
been used for treatment of schizophrenia 
could inhibit the replication of T. gondii in 
cell culture (16). 
There are some risk factors for developing 
the disorder in later of life including winter 
or spring birth, urban birth, and prenatal and 
postnatal infections (17). Hence, environ-
mental studies have rekindled interest in the 
possible role of infectious agents in schizo-
phrenia (18). 
To explore further the association between 
Toxoplasma  infection and schizophrenia, 
this study was established to compare the 
amount of anti-Toxoplasma IgG antibodies 
between patients with schizophrenia and 
non- schizophrenia control group by ELISA. 
 
Materials and Methods 
 
This case-control study was carried out dur-
ing 2009 and 2010 in Tehran, Iran. This 
study was approved by the Ethical Commit-
tee of Tehran University of Medical Sci-
ences, Iran.  
 
Participants 
Sixty-two patients with schizophrenia were 
recruited from Roozbeh University Hospital, 
Tehran, Iran. The diagnosis was made by 
academic psychiatrists according to DSM-
IV-TR classification. To evaluate the posi-
tive and negative symptoms the PANSS 
(positive and negative symptoms scale) was 
used. All patients had no family history of 
schizophrenia, no history of head trauma and 
brain surgery. Blood samples were obtained 
from the patients and control groups in the 
morning. 
Control group consisted of 62 healthy volun-
teers. They were evaluated to rule out any 
medical and psychiatric disorders. The pa-
tient and control groups were matched as 
possible on socioeconomic status; dietary 
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habits (especially with regard to eating or 
drinking uncooked/undercooked meat, milk, 
or eggs); and age (average of 37.54± 9.75 
year in schizophrenic patients and 37.24 ± 
10.24 year in healthy volunteers). The fac-
tors of urban or rural areas were considered 
as well. There were no significant differ-
ences between two groups with respect to 
these factors (P>0.05). Duration of illness in 
schizophrenia patients was from 2 to 37 
years. 
Based on clinical features the schizophrenic 
patients were divided to three forms includ-
ing paranoid, undifferentiated, and disorgan-
ized types.  
 
 
Serological Technique 
Serum was separated from whole blood 
shortly after collection, and stored at–20˚C. 
Tachyzoites of  T. gondii, RH strain were 
collected from peritoneal cavity of mice in-
fected 3 days earlier. The organisms were 
centrifuged at 2000 rpm for 20 min, washed 
three times in phosphate buffer saline (PBS) 
pH 7.2, and disrupted by sonication. Lysed 
cells were centrifuged at 12000g for 1 hour 
at 4˚ C. The supernatant was collected and 
used as the soluble T. gondii antigen. Protein 
determination was performed using the 
Bradford method (19). 
To establish the ELISA method the 96 well 
microtitre plates (Nunc, Roskilde, Denmark) 
were coated with 5µg/ml of soluble T. gondii 
antigen in carbonate buffer (pH 9.6). Plates 
were incubated at 4 ˚ C for 24 hours and 
washed three times with PBST (PBS+20% 
tween 20) blocked with skimmed milk 1% 
(Merck, Darmstadt, Germany) in PBST and 
washed three times. Sera were diluted seri-
ally from 1:10 up to 1:6400 (1:10, 1:100, 
1:200, 1:400, 1:800, 1:1600, 1:3200 & 
1:6400) and added to each antigen wells in 
duplicate runs. Positive and negative sam-
ples were used in each experiment to con-
firm the accuracy of the method. Control 
samples were the sera collected previously 
tested and confirmed by IFA and ELISA 
methods. After incubating and washing, anti 
human IgG conjugated with horseradish per-
oxidase (HRP) enzyme (Dako, Produktions-
vej, Denmark) diluted 1:1000 in PBST was 
added; then orthophenylen diamidin (OPD) 
(Merck, Darmstadt, Germany) was added to 
each well as substrate. The reaction was 
stopped by adding the sulfuric acid (2N) and 
the optical density was read by an automated 
ELISA reader (BioTek, USA) at 490 nm 
(20). 
 
Statistical Analysis 
The cut-off was determined as the mean plus 
two times the standard deviation (M±2SD) 
of the optical density obtained for negative 
samples. Then the optical density for schizo-
phrenia patients and non-schizophrenia indi-
viduals were compared with the cut-off, 
separately. All data were analyzed by chi-
square at a confidence level of 95% and 99% 
by SPSS version 13.5.  
 
 
Results 
 
In this study, 62 cases with schizophrenia 
and 62 control individuals were compared 
for anti-  Toxoplasma  antibody by ELISA. 
The difference of anti T. gondii antibodies 
between schizophrenia patients (42 out of 
62) and control group (23 out of 62) were 
statistically significant ( P <0.01) (Table1). 
According to the ELISA test, the mean of 
optical density in sera from schizophrenia 
group was higher (0.58) in comparison with 
control group (0.22) (Table1).  
The sero-positivity rate for anti- T. gondii 
IgG antibodies in patients compared with 
control group (Fig.1) showed possible rela-
tionship between Toxoplasma infection and 
schizophrenia.  Alipour et al. Toxoplasma Infection in Schizophrenia Patients … 
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There was no significant difference between 
patients and control groups when socioeco-
nomic status, dietary habits, and age were 
compared.  
The schizophrenia patients were consisted of 
16 paranoid, 45 undifferentiated and 1 disor-
ganized types. Although the number of 
different types of disease was small, there 
was no statistically difference between type 
of schizophrenia and anti- T. gondii antibod-
ies.
 
 
Table 1: Distribution of anti-Toxoplasma antibodies by ELISA in schizophrenic and non-schizo-
phrenic individuals 
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Fig. 1: Comparison of anti- T. gondii antibodies between schizophrenic patients and non-
schizophrenia as control group 
 
Gender  ELISA
+
  Group       No. 
Male  Female 
Age (year) 
(M±SD) 
Mean 
of OD 
No.  % 
Schizophrenia 
patient 
62  39 
 
23 
 
37.54±9.75  0.58  42  67.7 
Control 
group 
62  26  36  37.24±10.24  0.22 
 
23 
 
37.1 
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Discussion  
 
In the present study, the sero- prevalence of 
anti- T. gondii antibodies was higher in pa-
tients with schizophrenia in comparison with 
control group. 
In recent years, serological studies on pa-
tients with schizophrenia have been carried 
out showing that anti- T. gondii antibodies 
were higher in patients than control groups 
(14, 15). In this study, patients with schizo-
phrenia had significantly elevated levels of 
IgG antibodies to T. gondii compared with 
controls (P <0. 01). This is in accordance 
with recent studies, which have suggested 
that infectious diseases could play a role in 
developing schizophrenia (14, 15). 
In humans, proliferating tachyzoites have 
been detected in glial cells in patients who 
had developed toxoplasmic encephalitis (2, 
21). In another presentation of toxoplasmic 
encephalitis, T. gondii bradyzoites were ob-
served in Purkinje cells in the cerebellum (2, 
22). T. gondii cysts have also been reported 
in astrocytes in humans (2, 23). 
Postmortem investigations of brains from 
individuals who had schizophrenia have re-
ported many glial abnormalities (18, 24), in-
cluding decreased numbers of astrocytes (18, 
25). Neurotransmitters such as dopamine, 
norepinephrine might be affected by tox-
oplasmosis, whom are affected in schizophr-
enic people as well (18, 26).  
The role of antibodies in psychotic patients 
infected with Toxoplasma was shown for the 
first time in 1953 (27). Torrey et al. reported 
antibodies in 495 (52%) of 961 psychiatric 
inpatients compared with 170 (25%) of 681 
controls. 
The prevalence of antibodies to T. gondii 
was higher in individuals with schizophrenia 
than in control groups and the infection with 
Toxoplasma  may confer a risk for schi-
zophrenia (28). 
Yazar et al. (18) compared 100 schizo-
phrenic patients with two control groups. In 
their study, 66% of schizophrenic patients 
and 23% of controls were positive for IgG 
titers. Leweke et al. (15) in Germany com-
pared 113 schizophrenic patients with 102 
normal people and reported antibodies in 
34% of cases compared with 16% of con-
trols. 
Saraei et al. compared 104 Iranian schizo-
phrenic patients with 114 normal people and 
reported  T. gondii antibodies in 55.3% of 
cases and 50.9% in control group (29). It is 
postulated that patients’ brain plays the most 
important role in the perception of the rela-
tion between toxoplasmosis and schizophre-
nia disease (3, 30, 31).  
In the present study, the seropositivity rate 
for anti-Toxoplasma  antibodies in patient 
group (67.7%) indicates that chronic Tox-
oplasma  infection is greater compared to 
control group (37.1%) (P<0.01).  
In conclusion, a significant correlation be-
tween Toxoplasma infection and schizophre-
nia might be expected. 
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